Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer Germantown, MD

Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer

Germantown, MD, August 8, 2016 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve

the quality of life and health of the planet, today announced the appointment of Andrew J. Last, Ph.D., as Chief Operating Officer effective August 29, 2016, reporting to Intrexon s President, Geno Germano. As Chief Operating Officer, Dr.

Last will oversee operations across the Company s multiple technology divisions and operating subsidiaries, driving efficiency and effectiveness in the application of the Company s assets toward its development projects, Exclusive Channel

Collaborations and direct market plays.

Mr. Germano, stated, Andy is a seasoned business executive who brings highly relevant talent and experience

to the COO position at Intrexon. His extensive expertise in both life sciences and agriculture fit in well with our engineering of biology approach with broad applications in these and other markets. We are excited to have him on board and

welcome him to the Intrexon team.

Dr. Last brings to Intrexon 30 years of experience spanning life sciences, including biotechnology, genomics,

clinical diagnostics, pharmaceuticals and agrochemicals, with several industry leading companies. Most recently Dr. Last served as the Executive Vice President and Chief Operating Officer of Affymetrix where he was responsible for directing

five business units, with each of the units leaders reporting to him, and overseeing strategic marketing, product management, R&D, clinical operations, regulatory affairs, QA/QC, and overall manufacturing operations for the

company. Additionally, as a member of the Affymetrix management team, he had a key role in defining and leading execution of the corporate turnaround strategy which led to a significant improvement of financial metrics culminating in the

company s $1.4 billion acquisition by Thermo Fisher Scientific. Dr. Last also previously served as the Chief Commercial Officer of Affymetrix directly managing global sales, product management, field marketing, service and support.

Intrexon has built an enviable portfolio of transformative molecular and cellular technology platforms, development collaborations with world class

partners as well as multiple direct market plays through its subsidiary companies, said Dr. Last. I am thrilled to be joining the management team, partnering with the operating units and contributing to building a world leading

Prior to joining Affymetrix, Dr. Last was Vice President, Global & Strategic Marketing of Becton Dickinson BioSciences Cell

Analysis Division & General Manager of Pharmingen, contributing as a member of the executive management team responsible for overall business strategy and execution, as well as driving development across a broad product portfolio. He has also

held executive positions with Applied Biosystems and Incyte Genomics. Further, Dr. Last spent a significant tenure with Monsanto Company serving in numerous leadership positions including Director, Worldwide Business and Category Management,

and Director, Ortho Home & Garden, for the Solaris Group, as well as Manager, Innovation and Product Development, Europe/Africa, for the Agricultural Group. He is currently an independent member of the Board of Directors of Oncocyte

Corporation. Dr. Last received a Bachelor s Degree in Biological Sciences from the University of Leicester, UK and a Master s degree in Bio-Aeronautics, as well as a Ph.D. in Agrochemical Specialization, from Cranfield University in

About Intrexon Corporation

Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality

of life and the health of the planet. The Company s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality,

Intrexon, Powering the

Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in

this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development

of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results

may be materially different from the plans, objectives and expectations expressed in this press release.

For more information regarding Intrexon Corporation, contact:

Vice President, Investor Relations

Tel: +1 (561) 410-7052

Senior Manager, Technical Communications

Tel: +1 (301) 556-9850